|1.||Romantsov, M G: 4 articles (01/2014 - 01/2011)|
|2.||Cooper, A J: 3 articles (12/2006 - 03/2002)|
|3.||Ershov, F I: 2 articles (01/2014 - 01/2013)|
|4.||Kovalenko, A L: 2 articles (01/2014 - 01/2011)|
|5.||Harris, N M: 2 articles (12/2006 - 07/2002)|
|6.||Crook, T J: 2 articles (07/2002 - 03/2002)|
|7.||Birch, B R: 2 articles (07/2002 - 03/2002)|
|8.||Dyer, J P: 2 articles (07/2002 - 03/2002)|
|9.||Yamada, Shigeki: 1 article (02/2016)|
|10.||Hayashi, Takahiro: 1 article (02/2016)|
06/01/2015 - "Following microscopic examination of the lesional smear, a diagnosis of cutaneous leishmaniasis was made, and the patient was successfully treated with intramuscular meglumine antimonate therapy. "
01/01/2013 - "A diagnosis of eyelid cutaneous leishmaniasis was made, and treatment was started with intramuscular meglumine antimonate. "
10/01/2012 - "Meglumine antimonate treatment enhances phagocytosis and TNF-α production by monocytes in human cutaneous leishmaniasis."
03/01/2001 - "Clinical response to supervised treatment of Colombian patients with cutaneous leishmaniasis was evaluated in a randomized controlled trial comparing 10 days versus 20 days of treatment with meglumine antimonate (20 mg Sb/kg/day). "
03/01/2001 - "Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species."
|2.||Urinary Bladder Neoplasms (Bladder Cancer)
01/01/1998 - "We have examined this question by exposing the superficial bladder cancer cell lines MGH-U1 and RT112 to meglumine-GLA (MeGLA) for time intervals ranging from 30 min to 2 h, at drug concentrations ranging from 1000 to 1.95 microg/ml. The MTT viable biomass assay was used to assess cell kill. "
07/01/2002 - "We assessed the efficacy of the novel intravesical formulation, meglumine gamma-linolenic acid (MeGLA), in a phase II trial, in patients with recurrent, superficial bladder cancer. "
07/01/2002 - "Intravesical meglumine gamma-linolenic acid in superficial bladder cancer: an efficacy study."
03/01/2002 - "The effects of meglumine gamma linolenic acid (MeGLA) on an organ culture model of superficial bladder cancer."
04/01/2009 - "Eicosapentaenoic acid has been tested in bladder cancer as a synergistic cytotoxic agent in the form of meglumine-eicosapentaenoic acid, although its mechanism of action is poorly understood in this cancer. "
03/01/1994 - "The high efficacy of our 10-day course of meglumine indicates that the currently recommended duration of 20 days may be unnecessary for infections caused by L. "
08/01/2005 - "Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model."
08/01/2005 - "The antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime) was evaluated in groups of rhesus monkeys with acute and chronic Leishmania (Viannia) braziliensis cutaneous infection. "
12/01/1994 - "Twelve days after infection, seven groups of mice were treated respectively with methylglucamine antimoniate (Glucantime) 5.56 mg/kg i.p. "
09/01/1992 - "Pentavalent antimony in the form of meglumine antimonate had an SD (84) of 416 mg/kg. In a second experiment in which animals were allowed to become more heavily infected, the drug was administered 10 days after infection and the animals were sacrificed after a further 2, 7, or 11 days. "
07/01/1979 - "It was found that the employment of Dimer-X (methylglucamine jocarmate) as contrast medium greatly reduced the frequency of secondary phenomena in 100 caudographies performed in subjects with lumbar and sciatic pain syndromes of orthopaedic interest. "
01/01/2015 - "No other adverse effects rather than injection pain with meglumine antimonite were observed. "
01/01/1982 - "There was significantly less pain and sensation of warmth after the injection of Iohexol than after Conray meglumine 282. "
12/01/1979 - "Pain accompanying leg venography: a comparison of sodium and methylglucamine diatrizoates."
07/19/1972 - "[Use of meglumine indomethacin in the treatment of pain due to neoplastic diseases]."
|5.||Visceral Leishmaniasis (Kala Azar)
08/01/2010 - "Detailed reports on the treatment of visceral leishmaniasis (VL) are scarce, particularly with regard to the utilization of antimoniate of N-methylglucamine. "
07/01/2009 - "Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment."
03/01/2002 - "This prospective study reports the clinical and laboratory findings in 50 children with visceral leishmaniasis, the value of a direct agglutination test (DAT), and the result of treatment with meglumine antimonate. "
04/01/1997 - "Primary and secondary unresponsiveness to meglumine has long been described in human visceral leishmaniasis. "
09/01/1958 - "[Test treatment with N-methylglucamine antimoniate in the diagnosis of kala-azar in children]."
|4.||Paromomycin (Paromomycin Sulfate)
|7.||Iothalamic Acid (Iotalamic Acid)
|5.||Cryotherapy (Therapy, Cold)